Clinical Decision-Making After Platinum Chemotherapy in Advanced Urothelial Carcinoma

In this segment, the speaker reviews real-world clinical decision-making for advanced urothelial (bladder) carcinoma after first-line platinum-based chemotherapy. A detailed case illustrates a 72-year-old patient with muscle-invasive bladder cancer and visceral metastases (lung and liver) who achieves a strong partial response to cisplatin plus gemcitabine. Building on data from the JAVELIN Bladder 100 study, the discussion explains why maintenance avelumab has replaced observation as the preferred approach for patients without disease progression, showing an overall survival benefit for those with complete response, partial response, or stable disease.

Key decision factors include tumor burden, PD-L1 status, tumor mutation burden, and metastatic pattern (bone-only or node-only vs high visceral burden). The segment emphasizes that, despite these differences, maintenance immunotherapy consistently improves outcomes. Throughout, the focus remains on balancing efficacy, toxicity, and quality of life, noting that maintenance immunotherapy is generally better tolerated than further chemotherapy and helps preserve everyday functioning.